CASI Pharmaceuticals Management
Management criteria checks 2/4
CASI Pharmaceuticals' CEO is Wei-Wu He, appointed in Apr 2019, has a tenure of 5.08 years. directly owns 5.29% of the company’s shares, worth $1.64M. The average tenure of the management team and the board of directors is 4.7 years and 8.8 years respectively.
Key information
Wei-Wu He
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5.1yrs |
| CEO ownership | 5.3% |
| Management average tenure | 4.7yrs |
| Board average tenure | 8.8yrs |
Recent management updates
Recent updates
Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%
Mar 12
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%
Dec 18We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate
Sep 02Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?
May 20Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M
Sep 23CASI Pharmaceuticals Q2 2022 Earnings Preview
Aug 11Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?
May 26Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts
Aug 14Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?
May 25Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?
Mar 16Companies Like CASI Pharmaceuticals (NASDAQ:CASI) Are In A Position To Invest In Growth
Feb 18
How Much Of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Do Insiders Own?
Jan 23Is CASI Pharmaceuticals' (NASDAQ:CASI) 205% Share Price Increase Well Justified?
Dec 28CASI Pharma's CD19 CAR-T nabs accelerated review in China for a type of blood cancer
Dec 23CASI Pharmaceuticals appoints Weihao Xu as CFO
Dec 16Growth Investors: Industry Analysts Just Upgraded Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Revenue Forecasts By 4.3%
Dec 02The Chairman & CEO of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Wei-Wu He, Just Bought 4.7% More Shares
Nov 27Casi Pharmaceuticals jumps 6% after CEO buys 227.5K shares
Nov 25Juventas initiates registration study for CNCT19
Nov 19CASI Pharmaceuticals EPS misses by $0.08, beats on revenue
Nov 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$27m |
| Sep 30 2023 | n/a | n/a | -US$40m |
| Jun 30 2023 | n/a | n/a | -US$41m |
| Mar 31 2023 | n/a | n/a | -US$38m |
| Dec 31 2022 | n/a | n/a | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$32m |
| Mar 31 2022 | n/a | n/a | -US$31m |
| Dec 31 2021 | US$10m | US$322k | -US$37m |
| Sep 30 2021 | n/a | n/a | -US$45m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$54m |
| Dec 31 2020 | US$819k | US$578k | -US$48m |
| Sep 30 2020 | n/a | n/a | -US$47m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$9m | US$424k | -US$46m |
| Sep 30 2019 | n/a | n/a | -US$43m |
| Jun 30 2019 | n/a | n/a | -US$42m |
| Mar 31 2019 | n/a | n/a | -US$32m |
| Dec 31 2018 | US$6m | n/a | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$23m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$13m |
| Dec 31 2017 | US$781k | n/a | -US$11m |
Compensation vs Market: Insufficient data to establish whether Wei-Wu's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Wei-Wu's compensation has increased whilst the company is unprofitable.
CEO
Wei-Wu He (58 yo)
5.1yrs
Tenure
US$9,665,359
Compensation
Dr. Wei-Wu He, Ph.D. is Chairman Emeritus at Genetron Holdings Limited since June 30, 2021 and served as its Chairman since May 2015 until June 30, 2021. He serves as Chairman and Chief Executive Officer a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 5.1yrs | US$9.67m | 5.29% $ 1.6m | |
| President | 4.7yrs | US$2.56m | 0.016% $ 4.8k | |
| Executive VP & Chief Medical Officer | 7.1yrs | US$1.18m | no data | |
| VP & Global Controller | 2.3yrs | no data | no data | |
| Chief Operating Officer | 6.2yrs | no data | no data | |
| General Counsel | 1.3yrs | no data | no data | |
| Chief Business Development Officer | no data | no data | no data | |
| Global Chief Commercial Officer | less than a year | no data | no data | |
| VP & Global Controller | no data | no data | no data |
4.7yrs
Average Tenure
54yo
Average Age
Experienced Management: CASI's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 12.3yrs | US$9.67m | 5.29% $ 1.6m | |
| Member of Scientific Advisory Board | 17.8yrs | no data | no data | |
| Independent Director | 11.1yrs | US$150.50k | no data | |
| Independent Director | no data | no data | no data | |
| Member of Clinical Advisory Board | 8.8yrs | no data | no data | |
| Independent Director | 1.2yrs | no data | no data | |
| Member of Clinical Advisory Board | 8.8yrs | no data | no data | |
| Independent Director | 8.3yrs | no data | no data |
8.8yrs
Average Tenure
56.5yo
Average Age
Experienced Board: CASI's board of directors are considered experienced (8.8 years average tenure).